Seminari di Ematologia Oncologica - Società Italiana di Ematologia

78 Seminari di Ematologia Oncologica
44. Falini B, Bigerna B, Fittozzi M, et al. ALK expression
defines a distinct group of T/null lymphomas (‘ALK
lymphomas’) with a wide morphological spectrum. Am
J Path. 1998; 153: 875-86.
45. Suzuki R, Kagami Y, Takeuchi K, et al. Prognostic
significance of CD56 expression for ALK-positive and
ALK-negative anaplastic large cell lymphoma of T/null
cell phenotype. Blood. 2000; 96: 2993-3000.
46. Amin HM, Lai R. Pathobiology of ALK+ anaplastic largecell
lymphoma. Blood 2007; 110: 2259-953.
47. Chiarle R, Voena C, Ambrogio C, et al. The anaplastic
lymphoma kinase in the pathogenesis of cancer. Nat
Rev Cancer. 2008; 8: 11-23.
48. Mourad N, Mounier N, Briere J, et al. Clinical, biologic
and pathologic features in 157 patients with
angioimmunoblastic T-cell lymphoma treated within the
Groupe d’Etude des Lymphomes de l’Adulte (GELA)
trials. Blood. 2008; 111: 4463-70.
49. Willenbrock K, Renne C, Gaulard P, et al. In
angioimmunoblastic T cell lymphoma, neoplastic T cells
may be a minor population. A molecular single cell and
immunohistochemical study. Virchows Arch. 2005; 446:
15-20.
50. Attygalle A, Al-jehani R, Diss TC, et al. Neoplastic T
cells in angioimmunoblastic T cell lymphoma express
CD10. Blood. 2002; 99: 627-33.
51. Attygalle AD, Kyriakou C, Dupui J, et al. Histologic
evolution of angioimmunoblastic T cell lymphoma in
consecutibe biopsies: clinical correlation and insights
into natural history and disease progression. Am J Surg
Pathol. 2007; 31: 1077-88.
52. Vinuesa CG, Tangye SG, Moser B, et al. Follicular B
helper T cells in antibody responses and autoimmunity.
Nat Rev Immunol. 2005; 5: 853-65.
53. Ree HJ, Kadin ME, Kikuchi M, et al. Bcl-6 expression
in reactive follicular hyperplasia, follicular lymphoma,
and angioimmunoblastic T cell lymphoma with
hyperplastic germinal centers: heterogeity of
intrafollicular T cells and their altered distribution in the
pathogenesis of angioimmunoblastic T cell lymphoma.
Hum Pathol. 1999; 30: 403-11.
54. de Leval L, Rickman DS, Thielen C, et al. The gene
expression profile of nodal peripheral T cell lymphoma
demonstrates a molecular link between
angioimmunoblastic T cell lymphoma and follicular
helper T cells. Blood. 2007; 109: 4952-63.
55. Nelson M, Horsman DE, Weisenburger DD, et al.
Cytogenetic abnormalities and clinical correlations in
peripheral T cell lymphoma. Br J Haematol. 2008; 141:
461-9.
56. Liang R. Advances in the management and monitoring
of extranodal NK/T cell lymphoma, nasal type. Br J
Haematol. 2009; 147: 13-21.
57. Wong KF, Chan JK, Cheung MM, et al. Bone marrow
involvment by nasal NK cell lymphomaat diagnosis is
uncommon. Am J Clin Pathol. 2001; 115: 266-70.
58. Ooi GC, Chim CS, Liang R, et al. Nasal T/NK cell
lymphoma: CT and MR imaging features of new clinicopathological
entity. Am J Roenterol. 174; 1141-45.
59. Suzuki R, Yamaguchi M, Izutsu K, et al. Prospective
measurement of EBV DNA in plasma and peripheral
blood mononuclear cells of Extranodal NK/T cell
Lymphoma, Nasal Type. Blood. 2009; 114 (22): abs 135.
60. Jaccard A, Gachard N, Coppo P, et al. A prospective
phase II trial of an L-Asparaginase containing
regimen in patients witn refractory or relapsing
Extranodal NK/T cell Lymphoma. [Abstract]. Blood.
2008; 112 (11): 579.
61. Sieniawski M, Angamuthu N, Boyd K, et al. Evaluation
of enteropathy-associated T cell lymphoma comparing
standard therapies with a novel regimen including
autologous stem cell transplantation. Blood. 2010; 115:
3664-70.
62. Daum S, Ullrich R, Heise W, et al. Intestinal non
Hodgkin’s lymphoma: a multicenter prospective
clinical study from the german Study Group on
Intestinal non Hodgkin’s Lymphoma. J Clin Oncol.
2003; 21: 2740-6.
63. Rongey C, Micallef I, Smyrk T, et al. Successful
treatment of entheropathy-associated T cell lymphoma
with autologous stem cell trasnplantation. Dig Dis Sci.
2006, 51: 1082-6.
64. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison
of a standard regimen (CHOP) with three intensive
chenotherapy regimens for advanced non-Hodgkin’s
lymphoma. N Engl J Med. 1993; 328: 1992-006.
65. Di Venuti G, Nawgiri R, Foss F. Denileukin diftitos and
hyper-CVAD in the treatment of human T cell
lymphotropic virus associated acute T cell
leucemia/lymphoma. Clin Lymphoma. 2003; 4: 176-8.
66. Karakas T, Bergmann L, Stutte HJ, et al. Peripheral T
cell lymphomas respond well to vincristine, adriamycin,
cyclophosphamide, prednisone and etoposide (VACPE)
and have similar outcome as high-grade B cell
lymphomas, Leuk Lymphoma. 1996; 24: 121-9.
67. Bouabdallah R, Delmer A, Xerri L, et al. ESHAP
chemotherapy regimen and 13-cis-reinoic acid in
elderly patients with intreated poor-prognosis peripheral
T cell lymphoma: a GELA phase II trial of feasibility and
efficacy. [Abstract]. Ann of Oncol. 2005; 16 (Suppl. 5):
v131 (abs.#322).
68. Delmer A, Mounier N, Gaulard P, et al. Intensified
induction therapy with etoposide (VP16) and high dose
cytarabina (AraC) in patients aged less than 60 years
with peripheral T-cell/NK lymphoma: Preliminary results
of the phase II GELA study LNH98 T7. [Abstract]. Proc
Am Soc Clin Oncol. 2003; 22: 591 (#2375).
69. Kim JG, Sohn SK, Chae YS, et al. Cancer Chemother
Pharmacol. 2006; 58: 35-39.
70. Schmitz N, Trumper L, Ziepert M, et al. Treatment and
prognosis of mature T cell and Nk cell lymphoma: an
analysis of patients with T cell lymphoma treated in
studies of the German high-grade Non-Hodgkin
Lymphoma Study Group. Blood. 2010; 116: 3418-25.